Sugi Predict

Sugi Predict / Targets / APOBEC3C

APOBEC3C

DNA dC->dU-editing enzyme APOBEC-3C · Q9NRW3 · APOBEC3C on Sugi Atlas →

0 patent compounds predicted against APOBEC3C, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to APOBEC3C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Efficacy of Adaptogens in Patients With Long COVID-19 PHASE2/PHASE3COMPLETED
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency PHASE1/PHASE2RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer PHASE2RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector PHASE1COMPLETED
A Safety Study of SGN-CD33A in AML Patients PHASE1COMPLETED
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects PHASE1COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects PHASE1COMPLETED
Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy nanNOT_YET_RECRUITING
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Investigation of ADA Enzyme Deficiency nanUNKNOWN
COsegregation of VARiants in Panel of Genes nanRECRUITING
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
Natural History of Autosomal Dominant Hearing Loss nanRECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates nanCOMPLETED
Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression nanCOMPLETED
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma nanACTIVE_NOT_RECRUITING
DNA Adductomics for Colorectal Cancer Investigation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a APOBEC3C binder may also engage these)

ProteinNameSimilarity
Q694B5 — 1.000 Q694B5 →
Q7YR23 — 0.993 Q7YR23 →
Q4VDN5 — 0.991 Q4VDN5 →
Q8IUX4 — 0.991 Q8IUX4 →
APOBEC3G DNA dC->dU-editing enzyme APOBEC-3G 0.989 landscape →
Q694C4 — 0.989 Q694C4 →
Q694C1 — 0.988 Q694C1 →
Q694B6 — 0.988 Q694B6 →
APOBEC3B DNA dC->dU-editing enzyme APOBEC-3B 0.987 landscape →
Q7YR25 — 0.987 Q7YR25 →
Q7YR24 — 0.986 Q7YR24 →
Q694C2 — 0.986 Q694C2 →
Q694C5 — 0.985 Q694C5 →
Q694B7 — 0.985 Q694B7 →
Q694B9 — 0.985 Q694B9 →
Q694C0 — 0.983 Q694C0 →
Q96AK3 — 0.983 Q96AK3 →
Q694B8 — 0.981 Q694B8 →
A9QA56 — 0.980 A9QA56 →
Q1WBT4 — 0.978 Q1WBT4 →
Q6NTF7 — 0.978 Q6NTF7 →
P60705 — 0.974 P60705 →
Q9GZX7 — 0.971 Q9GZX7 →
P60704 — 0.971 P60704 →
Q19Q52 — 0.970 Q19Q52 →
Q99J72 — 0.969 Q99J72 →
Q75W64 — 0.969 Q75W64 →
APOBEC3A DNA dC->dU-editing enzyme APOBEC-3A 0.968 landscape →
Q9WVE0 — 0.962 Q9WVE0 →
Q2PT36 — 0.962 Q2PT36 →